RATIONALE: Respiratory virus infections are associated with chronic obstructive pulmonary disease (COPD) exacerbations, but a causative relationship has not been proven. Studies of naturally occurring exacerbations are difficult and the mechanisms linking virus infection to exacerbations are poorly understood. We hypothesized that experimental rhinovirus infection in subjects with COPD would reproduce the features of naturally occurring COPD exacerbations and is a valid model of COPD exacerbations. OBJECTIVES: To evaluate experimental rhinovirus infection as a model of COPD exacerbation and to investigate the mechanisms of virus-induced exacerbations. METHODS: We used experimental rhinovirus infection in 13 subjects with COPD and 13 nonobstructed control subjects to investigate clinical, physiologic, pathologic, and antiviral responses and relationships between virus load and these outcomes. MEASUREMENTS AND MAIN RESULTS: Clinical data; inflammatory mediators in blood, sputum, and bronchoalveolar lavage; and viral load in nasal lavage, sputum, and bronchoalveolar lavage were measured at baseline and after infection with rhinovirus 16. After rhinovirus infection subjects with COPD developed lower respiratory symptoms, airflow obstruction, and systemic and airway inflammation that were greater and more prolonged compared with the control group. Neutrophil markers in sputum related to clinical outcomes and virus load correlated with inflammatory markers. Virus load was higher and IFN production by bronchoalveolar lavage cells was impaired in the subjects with COPD. CONCLUSIONS: We have developed a new model of COPD exacerbation that strongly supports a causal relationship between rhinovirus infection and COPD exacerbations. Impaired IFN production and neutrophilic inflammation may be important mechanisms in virus-induced COPD exacerbations.
RATIONALE: Respiratory virus infections are associated with chronic obstructive pulmonary disease (COPD) exacerbations, but a causative relationship has not been proven. Studies of naturally occurring exacerbations are difficult and the mechanisms linking virus infection to exacerbations are poorly understood. We hypothesized that experimental rhinovirus infection in subjects with COPD would reproduce the features of naturally occurring COPD exacerbations and is a valid model of COPD exacerbations. OBJECTIVES: To evaluate experimental rhinovirus infection as a model of COPD exacerbation and to investigate the mechanisms of virus-induced exacerbations. METHODS: We used experimental rhinovirus infection in 13 subjects with COPD and 13 nonobstructed control subjects to investigate clinical, physiologic, pathologic, and antiviral responses and relationships between virus load and these outcomes. MEASUREMENTS AND MAIN RESULTS: Clinical data; inflammatory mediators in blood, sputum, and bronchoalveolar lavage; and viral load in nasal lavage, sputum, and bronchoalveolar lavage were measured at baseline and after infection with rhinovirus 16. After rhinovirus infection subjects with COPD developed lower respiratory symptoms, airflow obstruction, and systemic and airway inflammation that were greater and more prolonged compared with the control group. Neutrophil markers in sputum related to clinical outcomes and virus load correlated with inflammatory markers. Virus load was higher and IFN production by bronchoalveolar lavage cells was impaired in the subjects with COPD. CONCLUSIONS: We have developed a new model of COPD exacerbation that strongly supports a causal relationship between rhinovirus infection and COPD exacerbations. Impaired IFN production and neutrophilic inflammation may be important mechanisms in virus-induced COPD exacerbations.
Authors: G Rohde; A Wiethege; I Borg; M Kauth; T T Bauer; A Gillissen; A Bufe; G Schultze-Werninghaus Journal: Thorax Date: 2003-01 Impact factor: 9.139
Authors: J David Beckham; Ana Cadena; Jiejian Lin; Pedro A Piedra; W Paul Glezen; Stephen B Greenberg; Robert L Atmar Journal: J Infect Date: 2005-05 Impact factor: 6.072
Authors: Gavin C Donaldson; Martin Law; Beverly Kowlessar; Richa Singh; Simon E Brill; James P Allinson; Jadwiga A Wedzicha Journal: Am J Respir Crit Care Med Date: 2015-10-15 Impact factor: 21.405
Authors: Catherine Spickler; Julie Lippens; Marie-Kristine Laberge; Sophie Desmeules; Édith Bellavance; Michel Garneau; Tim Guo; Oliver Hucke; Pieter Leyssen; Johan Neyts; Fréderic H Vaillancourt; Anne Décor; Jeff O'Meara; Michael Franti; Annick Gauthier Journal: Antimicrob Agents Chemother Date: 2013-05-06 Impact factor: 5.191
Authors: Richard Hewitt; Hugo Farne; Andrew Ritchie; Emma Luke; Sebastian L Johnston; Patrick Mallia Journal: Ther Adv Respir Dis Date: 2015-11-26 Impact factor: 4.031
Authors: Santtu Heinonen; Tuomas Jartti; Carla Garcia; Silvia Oliva; Cynthia Smitherman; Esperanza Anguiano; Wouter A A de Steenhuijsen Piters; Tytti Vuorinen; Olli Ruuskanen; Blerta Dimo; Nicolas M Suarez; Virginia Pascual; Octavio Ramilo; Asuncion Mejias Journal: Am J Respir Crit Care Med Date: 2016-04-01 Impact factor: 21.405